Abstract
Nonmotor symptoms (NMS) are very common in Parkinson's disease (PD) and may result in significant disability. The increased focus on these important clinical features represents a major advance in the care of PD patients. In this article, we provide an overview of recent developments in the field.
MeSH terms
-
Antiparkinson Agents / adverse effects
-
Behavioral Symptoms / etiology*
-
Cognition Disorders / etiology*
-
Deep Brain Stimulation / methods
-
Disability Evaluation
-
Dopamine / metabolism
-
Humans
-
Lewy Bodies / pathology
-
Neuropsychological Tests
-
Olfaction Disorders / etiology*
-
Parkinson Disease / complications*
-
Parkinson Disease / drug therapy
-
Parkinson Disease / pathology
-
Parkinson Disease / psychology*
-
Psychiatric Status Rating Scales
-
Quality of Life
-
Sick Role
Substances
-
Antiparkinson Agents
-
Dopamine